The Dow Jones popped this morning on news that a drug from Gilead Sciences (NASDAQ: GILD) showed some effectiveness in treating patients with coronavirus.
Shares of the drug company surged 16% after the bell on a report from a Chicago hospital that showed progress from Remdesivir.
Last week gave hope that stock markets had found a bottom, with a three-day rally that brought the Dow up over 20% from Monday's close through the end of Thursday's session.
However, stocks fell sharply on Friday, giving back some of the previous three days' gains from news that the U.S. has now become the country with the most confirmed coronavirus cases.
So the question remains: Are we at the bottom? And what will tell us that the market is making an investable bottom – one that will hold for more than a week or two?
With recession indicators flashing, investors are flocking to 10-year bonds that have the annual upside of just 1.5%.
But there are still market-beating stocks out there – in fact, one of our picks expects 103% growth.
And that brings us to the biotech industry.
There are some big biotech stocks to own right now that could deliver double, even triple-digit upside in less than 12 months.
It was the very first stock that I recommended on the very first day we published Private Briefing nearly eight years ago…
I've re-recommended the shares to my readers several times, and when something happened that I felt everyone should know about, we made sure to get the news out in Money Morning, too.
When I first wrote about it in 2011, shares were trading at $8.60. As of Wednesday morning, the stock was sitting near all-time highs at $171 – monumental gains of nearly 1,900%.
But I'm writing today because it's been a big winner for you, too – more than 149%.
And I don't think it's done, not by a long shot…
Let me tell you about the company - and all about this latest development...
Biotech companies are known for their potential to break out when a new drug comes to market, and today we're giving you two of the best biotech stocks to buy now.
Buying the top biotech stocks offers the sort of upside that's so hard to find right now.
At the end of 2018, the Federal Reserve told the market the water was warm, come in for a swim.
The market was happy to oblige. In fact, the S&P 500 has rebounded almost 11% to start 2019, nearly erasing all of the losses from December.
It's as if the sell-off never happened.
The Dow Jones today is projecting a 210-point gain on news that U.S. lawmakers have drafted an agreement that could prevent another government shutdown from coming this week.
While that's great news for stocks, an agreement with China would be an even bigger catalyst.
Thankfully there are plenty of bullish opportunities ahead for plugged-in investors...
The Dow Jones Industrial Average turned negative for the year after Wednesday's 608-point selloff.
This morning, the Dow projected a 136-point gain as the October's market rollercoaster continued.
Our Bill Patalon first introduced this biotech company to you on the very first day he published his Private Briefing service, and it's been a huge winner for you since.
Now, it's going to grow even bigger thanks to this new drug...
Killer profits are the backbone of investing.
Creating them feels good and can have a powerful impact on your life.
Surprisingly, this isn't difficult.
Contrary to what most investors believe, you don't have to have a hot tip or access to Wall Street's mahogany-lined halls, either.
Big profits are about getting your money working with one objective in mind...
